clinical trial · NCT06360640
A First-in-human Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of APC148 in Healthy Adults
Healthy SubjectsAPC148 and Placebo
brief summary
The purpose of this first-in-human trial is to investigate the safety, tolerability, and pharmacokinetics of APC148 after intravenous (IV) infusion of single ascending doses in healthy adults.
started
Sep 2, 2024
primary completion
Mar 10, 2025
completion
Mar 10, 2025
last updated
Mar 12, 2025
detailed description
Participants will receive a single 3-hours IV infusion of APC148 or placebo. 6 sequential cohorts are planned. The first 2 subjects in each cohort will be dosed in a sentinel fashion. The subjects will be followed for 7 days.
official title
A First-in-human, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of APC148 in Healthy Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol